CNS Pharmaceuticals (CNSP) Stock Statistics & Valuation Metrics

CNS Pharmaceuticals has a market cap or net worth of $1.83M. The enterprise value is -$5.57M.

CNS Pharmaceuticals has 811,449 shares outstanding. The number of shares has decreased by -2.65% in one year.

CNS Pharmaceuticals’s return on equity (ROE) is -3.50 and return on invested capital (ROIC) is -329.54%.

The current PE Ratio of CNS Pharmaceuticals is ―. CNS Pharmaceuticals’s PEG ratio is 0.00159.

In the last 12 months, CNS Pharmaceuticals had revenue of 0.00 and earned -15.85M in profits. Earnings per share was -35.75.

In the last 12 months, operating cash flow was -13.81M and capital expenditures -18.18K, giving a free cash flow of -13.83M billion.

CNS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CNS Pharmaceuticals upcoming earnings date is May 18, 2026, After Close (Confirmed).

CNS Pharmaceuticals as a current ratio of 1.98, with Debt / Equity ratio of 7.27%

In the past 12 months, CNS Pharmaceuticals has paid 0.00 in taxes.

CNS Pharmaceuticals EV to EBITDA ratio is 0.28, with an EV/FCF ratio of 0.33.

CNS Pharmaceuticals has $7.20M in cash and marketable securities with $328.57K in debt, giving a net cash position of $6.87M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CNS Pharmaceuticals is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy